To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
IOC chief said he believed more than 80 per cent of residents of the Olympic Village would be vaccinated or booked for vaccination ahead of the Games
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
'WHO issued an emergency use listing for Covovax, expanding the basket of WHO-validated vaccines against COVID-19. The vaccine is produced by the Serum Institute of India under licence from Novavax,' the world health body said in a tweet on Friday.
Investors cheered a sharp decline in the Current Account Deficit, which stands at a 4 year low as exports picked up and gold imports reduced.
'You have sufficient protection if you take the second dose of the Covishield vaccine at 12 weeks, because this vaccine works in a way where it provides protection in the first dose.'
The rap from both the US and UK drug regulators, including the latest one from the latter, has hit the scrip.
People with cancer have an appropriate, protective immune response to COVID-19 vaccines without experiencing any more side-effects than the general population, researchers said on Tuesday.
In a tweet, Prime Minister Narendra Modi said India is deeply honoured to be a 'long-trusted' partner in meeting the healthcare needs of the global community and that supplies of the vaccines to several countries will commence on Wednesday, and more will follow in the days ahead.
Out of the 447 adverse events following immunisation, only 3 required hospitalisation.
Senior Congress leader Manish Tewari and Union Health Minister Harsh Vardhan sparred on Twitter on Saturday with the Opposition leader raising questions over the emergency use approval given to the indigenously developed vaccine Covaxin and the Bharatiya Janata Party leader hitting back alleging that Tewari was only passionate about spreading rumours.
'We are hoping by March, the government allows us to export and give it to the private market.'
Bharat Biotech is in the middle of conducting a phase 3 trial with 22,000 subjects.
On production capacity of Covishield, the vaccine being manufactured and supplied by Serum in India under a licensing agreement with Oxford and AstraZeneca, he said the present capacity is 130 million doses per month and always try to increase it further.
Speaking during Prime Minister Narendra Modis video conference meeting with chief ministers of eight states which have reported high COVID-19 cases, Thackeray said the PM or Union Home Minister Amit Shah should convene a meeting of all parties to tell them about the seriousness of the situation.
So far, no other vaccine has been approved globally for children below 12 years. Sohini Das reports.
The Department of Health and Social Care said a total of 81,959,398 doses of COVID vaccines have been administered in the UK, with 46,227,101 people receiving a first dose (87.8 per cent) and 35,732,297 people receiving both doses (67.8 per cent).
Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.
The Central Drugs Standard Control Organisation has granted restricted emergency use authorisation to two new vaccines and a drug for COVID-19, taking the number of preventives and treatments available in India to 12.
The Biden administration had been under pressure to send the excess COVID-19 vaccines with the US to nations like India, which are facing severe vaccine shortages.
'Rolling out the vaccine is not a major challenge in India.'
Some critics contend that Japan's rush to secure supplies is driven largely by a political desire to show the world it is fully committed to hosting the Games.
The Union health ministry said in a statement on Monday that over 23,000 adverse events have been reported since the vaccination drive involving Covishield and Covaxin vaccines started in the country and of these 700 cases were reported to be serious.
The procurement and distribution will be centralised though the government is yet to take a call on the initial number of doses that will be procured.
Sputnik V is the third vaccine India has given the go-ahead to after 'Covishield', developed by Oxford University and AstraZeneca and 'Covaxin', the indigenous vaccine manufactured by Bharat Biotech. Covishield is manufactured by the Serum Institute of India.
The prime minister in his intervention at the session on "global economy and global health" also flagged the issue of facilitating international travel and talked about the mechanism of mutual recognition of vaccine certification as a means of achieving this, according to the text of his intervention shared by his office.
The researchers found that after being exposed to high levels of the novel coronavirus, none of the six monkeys that were given the vaccine developed viral pneumonia. Also, there was no sign that the vaccine had made the animals more vulnerable.
"The country wide vaccination exercise is being exponentially expanded to include those above 60 years of age and those above 45 years with co-morbidities, from March 1.
The international team of researchers combined lab-based experiments and epidemiology of vaccine breakthrough infections, showing that the Delta variant is better at replicating and spreading than other commonly-observed variants.
Pune-based Serum Institute of India (SII) is sitting on 200 million doses of Covishield that were manufactured in December and are set to expire in September. The company is likely to destroy these vaccines if nothing works out, Sohini Das reports.
The first dry run of the vaccination drive took place across 125 districts covering all States/UTs on January 2. The dry run was also conducted to familiarise the state, district, block, and hospital-level officers on all aspects of the COVID-19 rollout.
There is a process to be followed for EUL and pre-qualification of vaccines under which a company has to complete phase 3 trials and submit the whole data to the regulatory department of WHO which is examined by an expert advisory group," Swaminathan said.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
Of the 4.10 crore to be shared through COVAX, 1.40 crore will go to Latin America and the Caribbean nations and 1.60 crore to Asia.
Launches cloud-based version of solution to target mid-size clients in life sciences.
Director of the US National Institute of Allergy and Infectious Diseases, Dr Fauci said that India made the "incorrect assumption" that they were finished with COVID-19.
Some states have flagged the shortage of vaccines and expressed their inability to start vaccination of people above 18 years from Saturday
British nationals arriving in India, irrespective of their vaccination status, will have to undergo 10 days of mandatory quarantine from October 4 as part of the reciprocal actions initiated by the government following the vaccine certification row between the two countries.
Prime Minister Narendra Modi said on Wednesday that international travel should be made easier through mutual recognition of vaccine certificates, amid several countries adopting different sets of rules to allow foreigners to enter their territory in the wake of the COVID-19 pandemic.
Admitting that a vaccine or drug-based treatment is the only feasible long-term solution, he said the UK has accelerated this with promising vaccine development programmes and a collaboration between Oxford University and pharma major AstraZeneca was a vital step that could help rapidly advance the manufacture of a Covid-19 vaccine when it is ready.
